RESMED INC (RMD)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

RMD - RESMED INC

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS

ResMed is the global market leader in providing devices for the treatment of sleep apnoea and chronic pulmonary disease. Formed in Australia in 1989 the company listed on the ASX in 1999 and is also listed on the NYSE. ResMed's head office is in San Diego, California.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$36.59

02 Aug
2021

0.470

OPEN

$36.98

1.30%

HIGH

$37.09

0

LOW

$36.57

TARGET
$32.848 -10.2% downside
Franking for last dividend paid out: 0%
OTHER COMPANIES IN THE SAME SECTOR
ELX . PGC . AHZ . COH . FPH . IPD . LHC . NAN . SOM . HLA . MX1 . CAT . VHT . ONE . IDX . PME . CSX . 4DX . BRN . EMV . UBI . LDX . RAP . RVA . MEB . IME . PCK . CMP . CYC . IMR . VTI . OVN . EYE . AT1 . CBL .
FNARENA'S MARKET CONSENSUS FORECASTS
RMD: 1
Title FY21
Forecast
FY22
Forecast
EPS (cps) 70.8 xxx
DPS (cps) 21.2 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 51.4 xxx
Dividend Yield 0.6% xxx
Div Pay Ratio(%) 30.0% xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 1.46%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.58

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 12/05 - 3.5c (0%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2021 FactSet UK Limited. All rights reserved
Title 201520162017201820192020
EPS Basic xxxxxxxxxxxxxxx64.3
DPS All xxxxxxxxxxxxxxx18.0
Sales/Revenue xxxxxxxxxxxxxxx4,411.0 M
Book Value Per Share xxxxxxxxxxxxxxx250.3
Net Operating Cash Flow xxxxxxxxxxxxxxx1,196.7 M
Net Profit Margin xxxxxxxxxxxxxxx21.02 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.5

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

3

xxxxx-xxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

3

xxxxxxxxx xx xxxx xxxx xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Credit Suisse

14/07/2021

1

Outperform

$37.00

1.12%

Philips’ recall of its CPAP and BiPAP DreamStation 1 devices has provided ResMed with an unprecedented opportunity to structurally increase its market share, according to Credit Suisse.

The broker highlights Philips will be unable to service new patients while it replaces its current installed base, and ResMed has no other cloud-connected competitor. Credit Suisse lifts the target price to $37 from $29. The Outperform rating is unchanged.

On a long-term basis, the analyst forecasts ResMed will capture 5% additional market share (65% total share) of the global CPAP market, though still considers Philips a strong competitor going forward.

FORECAST
Credit Suisse forecasts a full year FY21 dividend of 21.05 cents and EPS of 70.02 cents.
Credit Suisse forecasts a full year FY22 dividend of 22.11 cents and EPS of 83.23 cents.

Macquarie

xx/xx/xxxx

1

xxxxxxx xx xxxxxxxxxx xxxx xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

RMD STOCK CHART